US Patent 10,603,282 (United States) Scope, Claim Coverage, and Patent Landscape for Doravirine + Lamivudine + Tenofovir Disoproxil Fumarate Bilayer Tablets
Executive summary. US Patent 10,603,282 is directed to a specific bilayer tablet architecture for a fixed-dose combination of doravirine in a first layer and lamivudine + tenofovir disoproxil fumarate (TDF) in a second layer, with doravirine presented as an amorphous dispersion using defined polymer classes (including HPMC-ASLG as a preferred embodiment). The claim set is composition-focused but is drafted to cover formulation composition choices (polymer, glidant, diluent, disintegrant, lubricants) and dose-strength specific compositions (notably 50/150/150 mg and 100/300/300 mg doravirine/lamivudine/TDF), plus manufacturing-adjacent structural variants (co-granulated vs separately granulated actives in layer 2) and finished-product features (film coat; polishing aid).
What is US Drug Patent 10,603,282 claim scope for a doravirine bilayer tablet?
Short answer. Claim 1 sets the outer boundary: a bilayer tablet with (i) an amorphous dispersion formulation of doravirine in layer 1 and (ii) lamivudine + TDF in layer 2, with the amorphous dispersion optionally further defined by polymer selection in dependent claims.
Claim 1: the core infringement anchor
- Preamble/structure: “pharmaceutical composition, which is a bilayer tablet”
- Layer 1: “amorphous dispersion formulation of doravirine”
- Layer 2: “lamivudine and tenofovir disoproxil fumarate”
Practical implication. Any US commercial or ANDA/505(b)(2) design-around that retains a bilayer with these functional layer definitions and maintains doravirine as an amorphous dispersion is in the direct claim zone, even if excipients differ (unless the design changes eliminate the “amorphous dispersion” requirement or changes to non-bilayer architecture).
Claims 2–4: the amorphous dispersion polymer locks
- Claim 2: doravirine amorphous dispersion comprises doravirine and a polymer
- Claim 3: polymer is from a closed list including:
- HPMC-ASLG
- HPMCP phthalate/acetate phthalate family members
- cellulose acetate derivatives (phthalate, trimellitate, terephthalate, isophthalate)
- PVP and PVP-PVAc copolymers
- Claim 4: polymer is HPMC-ASLG (dependent narrowing)
Practical implication.
- If a competitor uses amorphous dispersion but substitutes a polymer outside the listed group, claims 3/4 narrow out, but claim 1 may still be asserted if “amorphous dispersion” is met and the polymer identity is not a limitation in claim 1.
- If a competitor uses a polymer that is within the enumerated set, they are pulled into the tighter dependent coverage immediately.
Claims 5–7: layer-1 excipient cluster coverage
- Claim 5: layer 1 includes amorphous dispersion of doravirine plus:
- glidant, diluent, disintegrant, lubricant
- Claim 6: glidant/diluent/disintegrant/lubricant each selected from enumerated groups (colloidal silica, talc, starch; lactose/mannitol/MCC/Ca salts; croscarmellose sodium/starch/crospovidone/sodium starch glycolate; magnesium stearate/stearic acid/sodium stearyl fumarate)
- Claim 7: specific sub-combination:
- glidant: colloidal silica
- diluent: microcrystalline cellulose
- disintegrant: croscarmellose sodium
- lubricant: magnesium stearate
Practical implication. These claims are most useful in enforcement where a competitor’s formulation composition aligns with the exact excipient selection. They also create a structured “staged” litigation narrative: claim 1 for architecture/amorphous dispersion; dependent claims for formulation mimicry.
Claims 8–10: layer-2 excipient cluster coverage
- Claim 8: layer 2 includes lamivudine + TDF plus glidant, diluent, disintegrant, lubricants
- Claim 9: enumerated sets match claim 6-type options
- Claim 10: specific sub-combination:
- glidant: colloidal silica
- diluent: microcrystalline cellulose
- disintegrant: croscarmellose sodium
- lubricants: magnesium stearate and sodium stearyl fumarate
Claims 11–12: actives presentation in layer 2
- Claim 11: lamivudine and TDF are co-granulated
- Claim 12: lamivudine and TDF are separately granulated
Practical implication. These are structural/manufacturing-adjacent limitations that can matter for both formulation design-around and for evidence gathering (batch records, granulation method disclosures, formulation process descriptions).
Claims 13–14: finished product features
- Claim 13: composition comprises a film coat
- Claim 14: composition comprises a polishing aid
These are broad “product form” limitations that typically do not isolate a competitor unless the competitor uses a substantially different finishing system.
Claims 15–19: dose-strength and composition recitations
- Claim 15: 50 mg doravirine / 150 mg lamivudine / 150 mg TDF
- Claim 16: 100 mg doravirine / 300 mg lamivudine / 300 mg TDF
- Claims 17–18: detailed ingredient tables for the 50/150/150 and 100/300/300 strengths, respectively (including intragranular/extragranular distributions and a specific film coating system “Opadry II 39K”, plus film-coating weights, wax content in at least one embodiment)
- Claim 19: a further detailed ingredient allocation table, with layered intragranular/extragranular distribution of MCC, croscarmellose, silica, stearyl fumarate, magnesium stearate, plus film-coating.
Practical implication.
- Claims 17–19 create enforceable “exact match” targets when competitors replicate the detailed intragranular/extragranular distribution and excipient quantitative scheme.
- Claims 15–16 also allow a less detailed but strength-limited assertion.
How broad are the polymer and excipient limitations under US 10,603,282?
Short answer. The polymer limitation is only explicitly required in dependent claims (2–4). The core claim 1 only requires doravirine in an amorphous dispersion formulation, not the polymer identity. Excipient limitations are introduced in claims 5–10.
Polymer coverage: enumerated class but still broad within those families
The polymer list in claim 3 includes:
- Enteric-ish cellulose acetate phthalate/trimellitate/tere/isophthalate variants
- HPMC-ASLG (preferred via claim 4)
- PVP and PVP-PVAc copolymers
Claim-coverage consequence.
- If a competitor uses an amorphous dispersion of doravirine with one of these polymers, the formulation is tightly enveloped under claims 3 and often 4.
- If a competitor uses an alternative polymer, claim 1 can remain at issue; claims 3 and 4 fall away.
Excipient coverage: “choose-from lists” enable partial engineering
Glidant options: colloidal silica, silicone dioxide, talc, starch
Diluent options: lactose variants, mannitol, MCC, calcium phosphate dibasic, Ca carbonate, Mg carbonate
Disintegrant options: croscarmellose sodium, starch, crospovidone, sodium starch glycolate
Lubricants options: magnesium stearate, stearic acid, sodium stearyl fumarate
With sub-combination narrowing in claims 7 and 10.
Design-around reality. Switching any one excipient category to a non-listed member eliminates claims 6/9 dependent coverage, but does not defeat claim 1 unless the excipient change also disrupts “amorphous dispersion” performance and the bilayer definition.
What formulation design variants are explicitly covered (co-granulated vs separately granulated, film-coated, polishing aid)?
Short answer. The patent explicitly distinguishes co-granulation vs separate granulation for lamivudine and TDF, and explicitly covers film coating and polishing aid as product features.
Actives granulation variant
- Co-granulated: claim 11
- Separately granulated: claim 12
Infringement consequence. Competitors typically select one approach for granule preparation. Either approach can fall into the claim set.
Finishing/coat variant
- Film coat: claim 13
- Polishing aid: claim 14
Infringement consequence. These are usually standard in commercial tablets, making these claims likely to be met if the competitor produces a conventional film-coated tablet.
What dose strengths and quantitative embodiments does US 10,603,282 cover?
Short answer. The patent includes explicit strength recitations and at least two detailed quantitative embodiments, tied to doravirine/lamivudine/TDF dosing ratios.
Dose ratio coverage
| Claim |
Doravirine (mg) |
Lamivudine (mg) |
TDF (mg) |
Intended use |
| 15 |
50 |
150 |
150 |
50/150/150 strength |
| 16 |
100 |
300 |
300 |
100/300/300 strength |
Quantitative embodiment coverage (detailed tables)
- Claim 17: includes a full layered composition with:
- HPMC-ASLG at 200.0 mg in layer 1
- layer weights of 500 mg each layer and core tablet weight 1000 mg
- Opadry II 39K film coat 25.00 mg and film-coated weight 1025 mg
- Claim 18: includes:
- HPMC-ASLG 400.0 mg in layer 1
- layer weights 780 mg each, core tablet weight 1560 mg
- Opadry II 39K 39.00 mg
- Carnauba wax 0.05 mg
- film-coated weight 1599 mg
- Claim 19: includes another detailed allocation scheme for the 100/300/300 concept with revised intragranular/extragranular excipient distribution.
Enforcement consequence. If a competitor uses the same layering and excipient partitioning, claims 17–19 become the highest-value targets.
What patent landscape issues matter for a bilayer doravirine/TDF/lamivudine combination in the US?
Short answer. The landscape typically fragments across four buckets: (1) composition and formulation patents like 10,603,282, (2) fixed-dose combination patent coverage, (3) method-of-treatment/use patents, and (4) process and solid-state form patents (granulation, amorphous dispersion formation, enteric polymers). The bilayer + amorphous dispersion architecture is a specific formulation strategy that narrows design-around options.
Where US 10,603,282 sits in the estate logic
- It is not merely a “fixed-dose combination” claim.
- It is a solid dosage architecture claim tied to:
- bilayer tablet geometry,
- doravirine as amorphous dispersion,
- polymer and excipient selections,
- dose-strength definitions and quantitative embodiments.
Estate consequence. Even if earlier patents protect the combination or dosing regimen, 10,603,282 can support an infringement theory focused on the drug product structure used by a generic applicant or licensee.
How could generic entry be risked under US 10,603,282 (ANDA/505(b)(2))?
Short answer. The core risk is whether the proposed generic’s product:
- is a bilayer tablet,
- uses doravirine in amorphous dispersion, and
- matches the dependent formulations (polymer and excipient selections) or the dose-strength quantitative embodiments.
Key risk checkpoints for product design
- Architecture: bilayer or not
- Drug physical state/form: amorphous dispersion maintained or replaced
- Polymer class: if within claim 3 list, dependent exposure rises
- Layer excipients: match to claim 6/9 options and claim 7/10 exemplars
- Lamivudine/TDF granulation: co vs separate granulation
- Finished product: film-coated and presence of polishing aid
Likelihood assessment framework
- Closest-case (higher risk): bilayer architecture + doravirine amorphous dispersion + polymer in claim 3 list + similar excipient sets + film coat.
- Partial design-around (medium risk): bilayer architecture retained but polymer/excipient set changed away from dependent claims; claim 1 still likely asserted if amorphous dispersion is preserved.
- Strong design-around (lower risk): eliminate one or more of claim 1’s essential features, especially bilayer structure or “amorphous dispersion formulation” requirement.
What litigation posture is implied by the claim structure (and what it enables in enforcement)?
Short answer. The layered claim structure supports both broad and narrow infringement arguments.
Claim strategy enabled by dependent nesting
- Claim 1: establish the core product features.
- Claims 2–4: show doravirine amorphous dispersion polymer choice.
- Claims 5–10: show excipient selections per layer.
- Claims 11–12: show granulation approach.
- Claims 15–19: show strength and quantitative embodiment match.
Evidence implication. Discovery can target:
- composition sheets and batch records to map excipient identity,
- analytical data showing amorphous dispersion,
- tablet manufacturing documentation establishing layering and bilayer formation,
- film coating formulation and polishing step descriptions.
Key Takeaways
- US 10,603,282 is a formulation-architecture patent centered on a bilayer tablet with doravirine amorphous dispersion in layer 1 and lamivudine + TDF in layer 2.
- Dependent claims materially expand coverage via:
- polymer lists for the doravirine amorphous dispersion (including HPMC-ASLG),
- defined excipient category sets per layer (glidant/diluent/disintegrant/lubricant),
- specific sub-combinations (notably layer 1: colloidal silica + MCC + croscarmellose sodium + magnesium stearate; layer 2: similar but with specified lubricants),
- co-granulation vs separate granulation for lamivudine and TDF,
- film coating and polishing aid.
- The patent includes dose strength coverage (50/150/150 and 100/300/300) and multiple detailed quantitative embodiments, which are high-value targets in infringement analysis.
- For generic entry, the dominant risk hinges on whether the product keeps bilayer structure and doravirine amorphous dispersion; dependent risks rise quickly if polymer and excipient selections match the enumerated options or the detailed tables.
FAQs
-
What single feature most directly differentiates a non-infringing design around US 10,603,282?
Eliminating either the bilayer tablet architecture or the requirement that doravirine is in an amorphous dispersion formulation.
-
Does US 10,603,282 require HPMC-ASLG?
Not in claim 1; HPMC-ASLG is required only in dependent claim 4 (as specified in your claim set).
-
How do the claims treat lamivudine/TDF manufacturing differences?
The patent covers both co-granulated (claim 11) and separately granulated (claim 12) preparation approaches for lamivudine and TDF.
-
Are film coating and polishing steps part of the patent scope?
Yes, via dependent claims 13 (film coat) and 14 (polishing aid).
-
Which claims are most relevant to strength-specific generic exposure?
The strength recitations in claims 15 and 16 and the detailed ingredient tables in claims 17–19.
References
- US Patent 10,603,282. (United States).
